Filippo Pietrantonio discusses overcoming resistance in metastatic colorectal cancer with innovative trials for amivantamab, enhancing treatment efficacy.
Filippo Pietrantonio, MD
Articles by Filippo Pietrantonio, MD
New research highlights amivantamab's potential in enhancing treatment outcomes for RAS/BRAF wild-type metastatic colorectal cancer, addressing resistance to standard therapies.
Latest Updated Articles
New OrigAMI-1 Data Signal Shift Beyond First-Gen EGFR Inhibitors in Metastatic CRCPublished: January 19th 2026 | Updated: